price intra-day
phase result accordion
downgrad perform
levodopa ap-cd/ld immedi releas ir-cd/ld fail detect statist
signific differ primari endpoint off-tim chang baselin
patient parkinson diseas pd top-lin result await
detail believ failur major setback ntec remov ap-cd/ld
model therebi updat revenu earn estim ntec besid
pd ntec still addit opportun drug includ proprietari
partnership novarti merck uncertain read
across ap-cd/ld ap applic differ diseas beyond pd
downgrad ntec perform outperform remov pt time
ntec ap design enhanc gastric retent novel drug deliveri
system compris multilay film contain ir controlled-releas cr
cd/ld estim elimin half-lif approxim hour
recent interview pd expert note current extended-
releas ld formul achiev similarli smooth pk profil
surpris today failur ntec recent complet pk studi
show ap-cd/ld daili tid dose reduc fluctuat
plasma level ld compar tradit intermitt cd/ld dose
recent pk studi ap-cd/ld dose tid met primari
ntec present post-hoc analysi show subset patient
requir maximum dose ld achiev numer separ
time ap vs ir howev find statist signific post-
hoc analysi suggest patient accord studi may
under-dos therefor caus studi fail
ask secondari endpoint chang baselin on-tim
without troublesom dyskinesia manag indic post-hoc analysi
show numer separ ap ir statist
signific number patient small sinc
patient dose qualifi believ find support
disappoint failur ntec ap-cd/ld especi
view studi valid deliveri technolog platform
applic base publish research identifi potenti candid
alreadi larg establish market remov ap-cd/ld model
uncertain read across applic downgrad perform
year price histori ntec
intec pharma drug develop
develop improv formul
analyst certif import disclosur see disclosur
neutral ntec share base failur ap-
cd/ld studi parkinson diseas lack clariti around
read across applic ap
ntec potenti leverag ap platform partner
outcom uncertain due failur ap-cd/ld
potenti updat undisclos partner program
trial initi ap-cbd/thc
ap-cbd/thc may progress rapidli later stage clinic
develop pain
note view ntec stock trade specul appropri risk-toler investor
revenues/royalti product sale
probabl approv
licens revenu mileston
good
research develop
sell gener administr
provis incom tax benefit
equival
stock price compani mention report
